Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,301–1,400 of 3,704
Fulgoni, V. L., Agler, A., Ricciuto, L., DiFrancesco, L., Williams, D., & Hertzler, S. R. (2024) · The Journal of Nutrition · doi:10.1016/j.tjnut.2024.07.022 · Cited by 8
Obesity and the Need for Bariatric Surgery in Nigeria: A Review
Adenuga, A. T., Salu, I. K., Bello, U. M., & Okaro, A. (2024) · Nigerian Postgraduate Medical Journal · doi:10.4103/npmj.npmj_157_24 · Cited by 12
Using Second-Generation Anti-Obesity Medications
Schmitz, S. H., & Aronne, L. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0002 · Cited by 11
Self-citationSafety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database
Khurana, A., Rabbani, S. A., El‐Tanani, M., Arora, M. K., Sharma, S., Dubey, H., Aljabali, A. A. A., & Tambuwala, M. M. (2024) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2024.101805 · Cited by 13
Obesity and Cardiometabolic Disease: Insights From Genetic Studies
Dash, S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.034 · Cited by 11
Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options
Schmitz, S. H., Saunders, K. H., & Aronne, L. J. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.09.003 · Cited by 12
Self-citationIzzi‐Engbeaya, C. N., & Dhillo, W. S. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.06.003 · Cited by 8
Koufakis, T., Maltese, G., & Kotsa, K. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106443 · Cited by 12
Obesity and diabetes in people of African ancestry with HIV
Cechin, L., Norcross, C., Oliveira, A., Hopkins, D., McGowan, B. M., & Post, F. A. (2022) · HIV Medicine · doi:10.1111/hiv.13413 · Cited by 7
“Tirzepatide resulted in a mean percentage weight reduction of 15%–21% over 72 weeks, which was accompanied by improvements in functional status, waist circumference, systolic blood pressure, plasma lipids, and fasting insulin and glucose [69], while earlier trials have shown high efficacy of tirzepatide in the managem…”
ResultGut–hormone triple agonists: clinical safety and metabolic benefits
Müller, T. D., & Tschöp, M. H. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02350-9 · Cited by 8
Future of bariatric surgery beyond simple weight loss: Metabolic surgery
Caiazzo, R. J., Marciniak, C., Rémond, A., Baud, G., & Pattou, F. N. (2023) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2023.01.005 · Cited by 15
Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review
Teague, M., Martinez, A., Walker, E., El-Rifai, M., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.02.003 · Cited by 8
Purcell, A. R., & Glastras, S. J. (2023) · Nutrients · doi:10.3390/nu15092155 · Cited by 9
“1% reduction in patients receiving a placebo [66].”
BackgroundObesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8
Chee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 10
“Another GLP-1/glucagon agonist that has advanced to human clinical trials is efinopegdutide, which has a relative potency ratio of approximately 2:1 for GLP1 and glucagon receptor, respectively [175].”
BackgroundInfluentialHuman HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamusPreprint
Tadross, J. A., Steuernagel, L., Dowsett, G. K. C., Kentistou, K. A., Lundh, S. H., Porniece, M., Klemm, P., Rainbow, K., Hvid, H., Kania, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557967 · Cited by 8
A Brain Reward Circuit Inhibited By Next-Generation Weight Loss DrugsPreprint
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A. K., Li, O. D.-A., Ogilvie, S., Keeler, A. B., Tian, G., Koita, O., Shi, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.12.628169 · Cited by 8
The No-Hunger Games: How GLP-1 Medication Adoption is Changing Consumer Food PurchasesPreprint
Hristakeva, S., Liaukonytė, J., & Feler, L. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5073929 · Cited by 8
Sex differences in GLP-1 signaling across speciesPreprint
Roseberry, T., Grossrubatscher, I., Krausz, T., Wang, Y.-J., Schwartz, M. W., & Tingley, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643822 · Cited by 8
“Patients taking these drugs routinely achieve >15% weight loss that can be sustained so long as the drug is continued 3–8 .”
Hoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“For example, Frias et al. showed some concerns regarding the randomization process [28], while Rosenstock et al. and Jastreboff et al. were judged as having some concerns related to missing outcome data [27,34].”
Advances in Primordial, Primary, and Secondary Prevention of Stroke in Diverse Populations
Adeniji, O. A., Olowoyo, P., Akinyemi, R., Fisher, M., & Owolabi, M. O. (2024) · Stroke · doi:10.1161/strokeaha.123.044231 · Cited by 9
Optimal Management of Obesity in Transplant Candidates and Recipients
Lam, J., Khan, M. Q., Watt, K. D. S., & Diwan, T. S. (2024) · Current Transplantation Reports · doi:10.1007/s40472-024-00434-8 · Cited by 8
Remission of type 2 diabetes mellitus
Nakhleh, A., Halfin, E., & Shehadeh, N. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i7.1384 · Cited by 10
Goldney, J., & Davies, M. J. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00977-2 · Cited by 7
“…consistently observed in people with obesity without T2D compared with people with T2D; for example, an estimated treatment difference of −17.8 percentage points (−19.3 to −16.3) with the highest dose of 15 mg tirzepatide ( n = 630) compared with the placebo ( n = 643) in the SURMOUNT-1 trial 6 .”
InfluentialOteng, A., Liu, L., Cui, Y., Gavrilova, O., Lü, H., Chen, M., Weinstein, L. S., Campbell, J. E., Lewis, J. E., Gribble, F. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182325 · Cited by 8
“During the past decade, highly potent and efficacious GLP1/GIP receptor co-agonists (e.g., tirzepatide) (57–59) have been developed for the treatment of T2D and obesity (60–62).”
Gong, J., Gao, F., Jiang, K., Xie, Q., Zhao, X., & Lei, Z. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14340 · Cited by 20
Old and new anti-obesity drugs
Dodangeh, S., & Hasani‐Ranjbar, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01512-5 · Cited by 8
“In the SURMOUNT-1 trial targeting non-diabetic patients with obesity, tirzepatide achieved an impressive 22.5% reduction in body weight after 72 weeks, surpassing other drugs [55].”
InfluentialMeyer, M., Núñez, J. E., Goyal, P., Silverman, D. N., van Berlo, J. H., & Maharaj, V. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.22 · Cited by 8
Krishnan, S., Srivastava, P. K., Attaluri, J., Nayeri, R., Chatterjee, D., Patel, J., Nsair, A., Budoff, M. J., & Nayeri, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12010019 · Cited by 13
Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy
Finkle, J., & Brost, B. C. (2025) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005825 · Cited by 7
“42 In the era of GLP-1 RAs producing 15 – 20% weight reduction, 1,39,43 the potential for improvement in reproductive health outcomes is welcomed but not well studied.”
Soliman, A. R., Saleem, H. M. E., Meligi, A. A. H. E., Naguib, M., Mohamed, R. S., Abdelaziz, G. R., Rakha, M., Abdelghaffar, S., Hamed, A. E., Hammad, H., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01564-w · Cited by 10
“Tirzepatide (TZP) resulted in impressive remission rates ranging from 66 to 81% after 52 weeks, depending on the drug dosage [106, 107].”
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Zhang, J., Wei, J., Lai, W., Sun, J., Bai, Y., Cao, H., Guo, J., & Su, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041651 · Cited by 9
“There is no increased risk of hypoglycemia, and the ability to lower HbA1c is superior to Semaglutide [52,53].”
Alfehaid, L., Yami, M. S. A., Almohareb, S. N., Alshaya, O. A., & Almutairi, A. R. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2465870 · Cited by 13
“Additionally, it has demonstrated the most substantial pharmacological weight loss effect, achieving a remarkable 20% reduction in body weight over 72 weeks in phase 3 randomized, controlled trials (RCT) [10,11].”
Mikdachi, H. E. A., & Dunsmoor-Su, R. F. (2025) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001015 · Cited by 10
Miedlich, S. U., & Lamberti, J. S. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15301 · Cited by 13
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Treating obesity in patients with depression: a narrative review and treatment recommendation
Kushner, P. R., Kahan, S. I., & McIntyre, R. S. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2478812 · Cited by 10
“…conditions ● Personal or family history of medullary thyroid carcinoma or type 2 multiple endocrine neoplasia syndrome Tirzepatide 15%–21% [127,128] Health conditions ● Personal or family history of medullary thyroid carcinoma or type 2 multiple endocrine neoplasia syndrome a All medications…”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Danielak, A., & Magierowski, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107741 · Cited by 9
Yao, Z., Tchang, B. G., Chae, K., Albert, M. H., Clark, J. M., & Blaha, M. J. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20083 · Cited by 13
“Emerging AOMs, such as nutrient-stimulated hormone therapies (e.g., semaglutide and tirzepatide), are becoming central to obesity management and have demonstrated substantial weight loss benefits with associated improvements in QoL, particularly in physical functioning [60–63].”
Health Disparities in Obesity Treatment Outcomes, Access, and Utilization
Ross, K. M., Worwag, K. E., Swanson, T. N., Shetty, A., & Barrett, K. L. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00639-7 · Cited by 10
“Earlier AOMs produced small additional weight losses (~ 2–3 kg) when added to comprehensive intervention [ 24 ]; however, newer incretin-based AOMs (e.g., semaglutide and tirzepa-tide) have demonstrated weight losses of ~ 15–20% [30 , 31 ].”
Golden, A. K., & Davis, J. M. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s509971 · Cited by 11
Overweight and Obesity — Capturing the Whole Picture
Aroda, V. R., & Perreault, L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2505819 · Cited by 7
Richards, R., Whitman, M., Wren, G., & Campion, P. (2025) · JMIR Formative Research · doi:10.2196/72577 · Cited by 7
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112294 · Cited by 12
Yamauchi, T., Asakura, T., Shingaki, T., Oura, T., & Katagiri, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16500 · Cited by 11
Review of the potential value of treatment targets in obesity management
Almohaileb, F. I., & le Roux, C. W. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2516522 · Cited by 8
“The SURMOUNT studies (2022–2023) with tirze-patide demonstrated 22% weight loss and significant health gains [36].”
Hoog, M. M., Kan, H. J., Deger, K. A., Sorensen, S. V., Neff, L. M., Bae, J. P., Hankosky, E. R., Murphy, M., Mojdami, D., Houisse, I., et al. (2025) · Obesity · doi:10.1002/oby.24310 · Cited by 9
Cholecystokinin: Clinical aspects of the new biology
Rehfeld, J. F. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20110 · Cited by 14
“…and glucose-dependent insulinotropic polypeptide (GIP), from which several drugs have already been derived and used widely in the treatment of diabetes and obesity, with additional candidates in the pipeline and potential for therapy of cardiovascular, renal, and cerebral diseases as well [2–4].”
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Inotropic effects of retatrutide in isolated human atrial preparations
Neumann, J., Ahlrep, U., Hofmann, B., & Gergs, U. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04421-3 · Cited by 7
Shaping the future of cardiometabolic innovation: advances and opportunities
Clemmensen, C., Gerhart‐Hines, Z., Schwartz, T. W., Zierath, J. R., & Sakamoto, K. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01343-5 · Cited by 7
Bjornson, A. M., Szabo, S. M., Donato, B. M. K., Gardner, M., & Kuti, E. L. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.25051 · Cited by 13
Schiavo, L., Santella, B., Mingo, M., Rossetti, G., Orio, M., & Pilone, V. (2025) · Nutrients · doi:10.3390/nu17152409 · Cited by 14
“At each monthly dietary counseling session, participants completed a standardized symptom and appetite tracking questionnaire, which gathered data on hunger, satiety, and any adverse gastrointestinal symptoms such as nausea, vomiting, diarrhea, or constipation [6,21–23].”
InfluentialEarly‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials
Gourgari, E., Srivastava, G., Kelly, A. S., Mojdami, D., Cao, D., Murphy, M. A., Karanikas, C. A., & Lee, C. J. (2025) · Obesity · doi:10.1002/oby.24348 · Cited by 10
Camajani, E., Masi, D., Spizzichini, M. L., Cori, C., Rossetti, R., Spoltore, M. E., Tuccinardi, D., Lubrano, C., Gnessi, L., Isidori, A. M., et al. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16658 · Cited by 7
García-Gorrita, C., Onofre, N. S., Merino-Torres, J. F., & Soriano, J. M. (2025) · Nutrients · doi:10.3390/nu17162699 · Cited by 10
Huh, Y. (2025) · Journal of Metabolic and Bariatric Surgery · doi:10.17476/jmbs.2025.14.2.97 · Cited by 14
Impact of Incretin-Based Therapy on Skeletal Muscle Health
Koceva, A., Janež, A., & Jensterle, M. (2025) · Medicina · doi:10.3390/medicina61091691 · Cited by 16
“In the SURMOUNT-1 cohort, patient-reported physical function assessed (SF-36) improved compared to placebo [10].”
InfluentialNeff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
“82,83 By augmenting the weight-loss effects of GLP-1 receptor agonists with the additional anorectic effects of glucagon signalling (including increased energy expenditure), GCGR-based dual and triple agonists may elicit even greater body weight reduction, which may be necessary to fully ameliorate…”
Angelopoulos, N., Livadas, S., Androulakis, I., Petkova, V., Rizoulis, A. A., Boniakos, A., Paparodis, R. D., Tzoulis, P., Mentzelopoulou, V., Florakis, D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109181 · Cited by 11
Johnson, H. H., Clift, A. K., Reisel, D., & Huang, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70244 · Cited by 7
“…tirzepatide and semaglutide reduce waist circumference, systolic blood pressure, glycated haemoglobin, and lipid levels, in line with earlier RCTs. 7,8 However, RCT populations do not reflect real-world effectiveness, whereas various factors including treatment adherence, lifestyle support, and…”
Maracle, B., Quan, S., Hamilton, P., Shaikh, A., Hazra, D., Lorenzetti, D., Gold, S. L., Raman, M., & St‐Pierre, J. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70485 · Cited by 19
Mehta, M., Rometo, D. A., Gusenoff, J. A., & Rubin, J. P. (2025) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000012672 · Cited by 16
The No-Hunger Games: How GLP-1 Medication Adoption Is Changing Consumer Food Demand
Hristakeva, S., Liaukonytė, J., & Feler, L. (2026) · Journal of Marketing Research · doi:10.1177/00222437251412834 · Cited by 25
“…research demonstrating the ef fi cacy of GLP-1 receptor agonists for substantial weight loss and cardiometabolic improvement (Garvey et al. 2023; Jastreboff et al. 2022; Wadden et al. 2023), their dependence on continued use for maintaining results (Aronne et al. 2024), and the high…”
InfluentialPharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
Self-citationGanamurali, N., & Sabarathinam, S. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70001 · Cited by 8
“23 Across the Phase 2 retatrutide program, adverse-event–related treatment discontinuations oc-curred in approximately 6%–17% of participants receiving active therapy, compared with 0%–4% among placebo recipients.”
Moradi, A., Denkova, R., Holcomb, K. Z., Rossi, A., & Ashourian, N. (2026) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojag011 · Cited by 13
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
“…to long-term metabolic complications, including sarcopenia, it is recommended that individuals undergoing treatment with GLP-1 RAs receive adequate protein intake and appropriate micronutrient supplementation to preserve muscle mass and function, thereby maximizing the clinical benefits of therapy.”
Hwang, J. H., & Laiteerapong, N. (2026) · Obesity · doi:10.1002/oby.70144 · Cited by 12
“The new criteria could expand treatment eligibility, increase demand for health care resources, and challenge current re-imbursement and prevention strategies in the era of costly but effective pharmacotherapy [19, 20].”
Crammond, P., Hastak, P., Delaney, A. P., & Sasson, S. C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1761361 · Cited by 11
“However more recently, disease modifying agents such as glucose-dependent insulino-tropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists such as Tirzepatide and Semaglutide have been widely repurposed for weight loss (222, 223).”
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“It is a fact that weight loss is especially variable between individuals 70,71 , and individual phenotypes poorly predict the degree of weight reduction 72 .”
InfluentialDobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
An inflection point in global public health
Greenberg, H. (2022) · Globalization and Health · doi:10.1186/s12992-022-00897-3 · Cited by 7
“Even if the new medications can reverse severe obesity; even if the price can be brought down to comfortable levels globally; and even if the side effect profile is not off-putting, there would be little impact on prevention [4].”
BackgroundThe need to personalise approaches for the prevention and management of obesity
Flint, S. W., & Batterham, R. L. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101944 · Cited by 8
de Oliveira, J. D., Schiavon, C. A., Oliveira, J. S., Santos, R. N., Damiani, L. P., Ikeoka, D., Santucci, E. V., Machado, R. H. V., Bortolotto, L. A., Berwanger, O. B., et al. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06711-2 · Cited by 9
Endoscopic Sleeve Gastroplasty in Those With a Body Mass Index of 27–30
Alqahtani, A. R., Alqahtani, O., Abdurabu, H. Y., Amro, N., Qahtani, A. R. A., Bokhari, A., Elahmedi, M. O., & Al-Darwish, A. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002476 · Cited by 7
“In addition, tirzepatide, a dual glucose-dependent insulino-tropic polypeptide and glucagon-like peptide-1 receptor agonist, was found to substantially reduce weight by 21% at 72 weeks, at a 15-mg once per week dose (29).”
Zlatkovic, J., Gasull, A. D., Hägg, D. A., Font‐Gironès, F., Bellman, J., Meister, B., Pálsdóttir, V., Ruud, J., Ohlsson, C., Dickson, S. L., et al. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13352 · Cited by 8
Navigating the Role of Anti-Obesity Agents Prior to Pregnancy: A Narrative Review
Goldberg, A. S., Dolatabadi, S., Dutton, H., & Benham, J. L. (2023) · Seminars in Reproductive Medicine · doi:10.1055/s-0043-1776795 · Cited by 9
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Lisco, G., Disoteo, O., Geronimo, V. D., Tullio, A. D., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., Jirillo, E., & Triggiani, V. (2024) · Endocrines · doi:10.3390/endocrines5010005 · Cited by 8
“[22].”
Wang, B., Peng, X., Fu, L., Lu, Z., Li, X., Tian, T., Xiao, X., Zhang, W., Guo, Z., Ouyang, L., et al. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18789 · Cited by 7
Ishikawa, T., Terai, N., Sato, R., Jimbo, R., Kobayashi, Y., Sato, T., Iwanaga, A., Sano, T., Yokoyama, J., & Honma, T. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3259-23 · Cited by 9
“A Phase II study demonstrated that semaglutide, a GLP-1A, inhibited NAFLD progression (5), Given the importance of weight loss in the treatment of NAFLD, the clinical application of GLP-1A in NAFLD holds promise (6).”
BackgroundMetabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?
Norton, B. C., Papaefthymiou, A., Telese, A., Mallik, R., Murino, A., Johnson, G., Murray, C. D., Makaronidis, J., & Haidry, R. J. (2024) · Gastrointestinal Disorders · doi:10.3390/gidisord6010013 · Cited by 7
“New pharmacological agents including GLP-1 receptor agonists and combined GLP-1/gastrointestinal peptide agonists are highly effective obesity and diabetic treatments [41,42].”
BackgroundKurevija, T., Šojat, D., Bosnić, Z., Mujaj, B., Canecki-Varžić, S., & Majnarić, L. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061617 · Cited by 9
“In addition, an increased CV risk can be ameliorated through the potent effect of these drugs—in particular, GLP-1ra and the emerging insulin secretion stimulating drug tirzepatide—on body weight reduction [50,51].”
BackgroundMartins, A. C., de la Torre, B. G., & Alberício, F. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00039 · Cited by 11
Otsuka, E., Kitamura, M., Funakoshi, S., Mukae, H., & Nishino, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1362242 · Cited by 8
“All tirzepatide doses are superior to all comparators in terms of body weight reduction (Jastreboff et al., 2022; Karagiannis et al., 2022).”
BackgroundMachado, M. F., Shunk, T., Hansen, G., Harvey, C., Fulford, B., Hauf, S., Schuh, O., Kaldas, M., Arcaroli, E., Ortiz, J. P., et al. (2024) · Cureus · doi:10.7759/cureus.66691 · Cited by 19
“Moreover, it has been reported that the use of GLP-1 RAs resulted in weight loss via the hormone’s effects on appetite reduction, increased satiety, and significant control of plasma lipid profiles [20,21].”
BackgroundEngineering Supramolecular Nanofiber Depots from a Glucagon-Like Peptide-1 Therapeutic
Chen, W., Xian, S., Webber, B., DeWolf, E. L., Schmidt, C. R., Kilmer, R., Liu, D., Power, E. M., & Webber, M. J. (2024) · ACS Nano · doi:10.1021/acsnano.4c10248 · Cited by 8
Cardiovascular effects of tirzepatide
Sumithran, P., Russell, A. W., & Zoungas, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0259 · Cited by 12
Wilson, R. L., & Aminian, A. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.01.027 · Cited by 8
Kuckuck, S., van der Valk, E. S., Scheurink, A. J. W., Lengton, R., Mohseni, M., Visser, J. A., Iyer, A. M., van den Berg, S. A. A., & van Rossum, E. F. C. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1010858 · Cited by 9
“In addition, fibroblast growth factor-21 (FGF21) and gastric-inhibitory polypeptide (GIP) are important regulators of glucose metabolism and insulin sensitivity (Seino and Yabe, 2013; Talukdar et al., 2016; Jastreboff et al., 2022).”
BackgroundStaico, B. M., Ferreira, L. M. D. V., Lima, M. G. D. O., Boz, N. W., Mendes, R. Y. R., Jeha, S. S., & Neves, S. L. S. (2023) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v4i4.2950 · Cited by 29
Designer GLP1 poly-agonist peptides in the management of diabesity
Statham, L., Pelling, M., Hanson, P., Kyrou, I., Randeva, H. S., & Barber, T. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204976 · Cited by 8
“Phase 3 trials of 2,539 participants demonstrated the superior glycemic and weight-loss efficacy of Tirzepatide compared with placebo, with its highest dose providing >20% body weight loss in the majority (57%) of participants in a 72-week trial, with minimal adverse effects [42].”
BackgroundBrodosi, L., Petroni, M. L., & Marchesini, G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2208746 · Cited by 7
“At standard weekly doses, tirzepatide was extremely effective and superior to any other comparator in inducing an optimum control of blood glucose concentrations [14], without inducing hypoglycemia, as well as a massive weight loss (on average from 15% to 20%) [15] and a favorable impact on quality of life [16], which…”
BackgroundFinkelstein, E. A., Chodavadia, P. A., & Strombotne, K. L. (2023) · Obesity · doi:10.1002/oby.23760 · Cited by 8
“This recommendation is timely as several new medications are expected to be available soon with much greater efficacy (and presumably costs) than what is currently on the market, and there will be substantial pressure on payers to fund these products [65].”
BackgroundNext Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists?
Abel, E. D. (2023) · New England Journal of Medicine · doi:10.1056/nejme2307285 · Cited by 9
Ferreira, J., Afonso, J., Longatto‐Filho, A., Roque, S., Carneiro, A. L., Vila, I., Silva, C., Cunha, C., Mesquita, A. V. S. C., Cotter, J., et al. (2023) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2023.09.094 · Cited by 10
Update on Endoscopic Treatments for Obesity
PESSORRUSSO, F. C. S., Mehta, S. V., & Sullivan, S. A. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00551-6 · Cited by 9
“Yet semaglu-tide has seen a sizeable weight loss of up to 16% TBW compared to 5.7% TBW with placebo at 68 weeks and tirzepatide has 20.9% TBW compared to 3.1% with placebo at 72 weeks [7, 8].”
InfluentialAdvancements in the management of obesity: a review of current evidence and emerging therapies
Abdalla, M. A., Ssemmondo, E., Mark‐Wagstaff, C., & Sathyapalan, T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347258 · Cited by 10
“[51–53].”
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.